Who Makes Wegovy: The Manufacturer and Its Products

Welcome to the PlexusDx Education Hub, where we translate the fast-moving world of GLP-1 therapy, weight-management protocols, and metabolic genetics into plain, decision-ready guidance. Explore the full Peptides & GLP-1 library.

Wegovy is the weight-management face of a much larger product family, and understanding who makes it clears up a lot of the confusion between similar-looking GLP-1 drugs. The maker is Novo Nordisk, and Wegovy is one of several products it fields. This piece places Wegovy in that lineup and against its main competitor.

Where Wegovy sits in the lineup

Wegovy is Novo Nordisk’s semaglutide 2.4 mg product, FDA-approved for chronic weight management in 2021. It shares its active ingredient with two stablemates: Ozempic (semaglutide, approved for type 2 diabetes in 2017) and Rybelsus (oral semaglutide, approved for type 2 diabetes in 2019). So while Wegovy is the weight-management label, the same molecule appears elsewhere under diabetes labels.

The rest of the Novo Nordisk portfolio

Beyond semaglutide, Novo Nordisk markets two liraglutide products: Victoza (approved for type 2 diabetes in 2010, gaining a cardiovascular indication in 2017) and Saxenda (liraglutide 3 mg, approved for chronic weight management in 2014). Its pipeline includes emerging obesity agents such as CagriSema, which combines cagrilintide with semaglutide. Together these span diabetes and weight management with overlapping mechanisms. Because several products share an active ingredient or a mechanism, the portfolio can look confusing at a glance; the clarifying detail is always the approved indication printed on each product’s label rather than the family resemblance between them.

Novo Nordisk versus its main competitor

The GLP-1 field is effectively a two-company contest, and the makers differ in molecular approach. Novo Nordisk favors GLP-1-selective compounds like semaglutide and liraglutide. Eli Lilly, by contrast, markets the only FDA-approved GIP/GLP-1 dual agonist, tirzepatide, plus the GLP-1-selective dulaglutide. Trials such as SURPASS-2 (tirzepatide versus semaglutide 1 mg in type 2 diabetes) and SUSTAIN 7 (semaglutide versus dulaglutide) shape the competitive picture, though direct weight-management head-to-head data are limited.

How pricing compares

List prices across branded products are broadly similar, typically $800 to $1,600 per month at U.S. list as of April 2026. Savings-card programs differ by product, and both companies run patient-assistance programs for eligible uninsured or underinsured patients. Compounded alternatives available through 503A pharmacies carry their own separate pricing.

The safety warnings both makers carry

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists from both companies carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and each is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects are the most common side effects, and rare serious events include pancreatitis, gallbladder events, and acute kidney injury when dehydration is present.

The PlexusDx position

PlexusDx does not sell branded Wegovy. It offers semaglutide and tirzepatide as compounded formulations through its Weight Management Protocols, including Semaglutide Injection and Semaglutide Oral, with published per-protocol pricing.

The genetic layer sitting underneath the pathway

Two people can follow an identical protocol and experience very different appetite shifts, energy, and tolerability. A meaningful part of that spread traces back to inherited biology. Variants in FTO influence hunger set-points and fat storage, MC4R helps govern the melanocortin appetite circuit, TCF7L2 is tied to glucose handling, and GLP1R shapes how the GLP-1 receptor itself behaves. The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights across this terrain, giving you and your clinician a portrait of the metabolic tendencies you started with. To be explicit: this is trait and pathway education, not a forecast of how you will respond to any drug or medication. It is the upstream context, the "test before you invest" step, that makes the conversation about any weight management protocol a more informed one.

Frequently Asked Questions

Who is the manufacturer of Wegovy?

Wegovy is manufactured by Novo Nordisk. It is the company’s semaglutide 2.4 mg product approved for chronic weight management in 2021. The same active ingredient, semaglutide, also appears in Novo Nordisk’s Ozempic and Rybelsus, which carry type 2 diabetes indications rather than a weight-management one.

Is Wegovy just Ozempic with a different name?

They share semaglutide as the active ingredient and the same maker, but they are distinct products with different approved uses, doses, and labels. Wegovy is approved for chronic weight management, whereas Ozempic is approved for type 2 diabetes. Coverage and prescribing follow the label rather than the shared molecule.

How does Wegovy’s maker compare with the competition?

Novo Nordisk emphasizes GLP-1-selective compounds, while Eli Lilly offers the only approved GIP/GLP-1 dual agonist, tirzepatide, plus dulaglutide. Trials like SURPASS-2 and SUSTAIN 7 inform comparisons, but direct weight-management head-to-head data are limited, so individual response and provider guidance matter most.

Can a genetic test tell me if Wegovy will work?

No. The Precision Peptide Genetic Test does not predict response to Wegovy or any specific product. It analyzes pathway-level variants such as FTO and MC4R, and TCF7L2 that shape baseline metabolic biology, providing upstream context that applies across the class rather than a drug-specific forecast.

Keep reading across the PlexusDx Education Hub for more evidence-based explainers on the GLP-1 pathway. Return to the education hub.